

Proteinase-activated receptor-1 (PAR1) and PAR2 mediate relaxation of guinea pig internal anal sphincter

Shih-Che Huang*

Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan
School of Medicine, I-Shou University, Kaohsiung, Taiwan



ARTICLE INFO

Article history:

Received 7 April 2013
Received in revised form 3 March 2014
Accepted 4 March 2014
Available online 11 March 2014

Keywords:

Proteinase-activated receptor
Internal anal sphincter
Motility
Trypsin
Thrombin

ABSTRACT

Activation of proteinase-activated receptor-1 (PAR₁) and PAR₂ stimulates contraction of the rat but relaxation of the guinea pig colon. The aim of the present study was to investigate PAR effects on internal anal sphincter (IAS) motility. We measured relaxation of isolated muscle strips from the guinea pig IAS caused by PAR agonists using isometric transducers. Reverse transcription polymerase chain reaction (RT-PCR) was performed to determine the existence of PAR. In the IAS, thrombin and PAR₁ peptide agonists TFLLR-NH₂ and SFLLRN-NH₂ evoked moderate to marked relaxation in a concentration-dependent manner. In addition, trypsin and PAR₂ peptide agonists 2-furoyl-LIGRLO-NH₂, SLIGRL-NH₂ and SLIGKV-NH₂ produced relaxation. In contrast, both PAR₁ and PAR₂ inactive control peptides did not elicit relaxation. Furthermore, the selective PAR₁ antagonist vorapaxar and PAR₂ antagonist GB 83 specifically inhibited thrombin and trypsin-induced relaxations, respectively. RT-PCR revealed the presence of PAR₁ and PAR₂ in the IAS. This indicates that PAR₁ and PAR₂ mediate the IAS relaxation. The relaxant responses of TFLLR-NH₂ and trypsin were attenuated by N(omega)-Nitro-L-arginine (L-NNA), indicating involvement of NO. These responses were not affected by tetrodotoxin, implying that the PAR effects are not neurally mediated. On the other hand, PAR₄ agonists GYPGKF-NH₂, GYPGQV-NH₂ and AYPGKF-NH₂ did not cause relaxation or contraction, suggesting that PAR₄ is not involved in the sphincter motility. Taken together, these results demonstrate that both PAR₁ and PAR₂ mediate relaxation of the guinea pig IAS through the NO pathway. PAR₁ and PAR₂ may regulate IAS tone and might be potential therapeutic targets for anal motility disorders.

© 2014 Elsevier B.V. All rights reserved.

1. Introduction

Proteinase-activated receptors (PARs) are a unique G protein-coupled receptor family activated by a variety of proteinases including thrombin and trypsin. Proteolysis of the PARs exposes receptor N-terminal sequences which act as activating ligands. Up to date, four subtypes of PARs, PAR₁, PAR₂, PAR₃, and PAR₄, have been described. The activating ligands are SFLLR, SLIGKV and GYPGQV for human PAR₁, PAR₂, and PAR₄, respectively. The PAR₃ peptide, TFRGAP, does not activate its receptor. Thrombin activates PAR₁ and PAR₄ whereas trypsin activates PAR₂. PARs are involved in aspects of both physiology and pathophysiology including inflammation disorders, cardiovascular diseases and cancer [1,2]. In the gastrointestinal system, PARs regulate gastrointestinal motility and secretion and may play important roles in colitis [2–4]. The gastrointestinal tract is exposed to trypsin, tryptase and bacterial proteinase, which can activate PARs [4,5]. Previous studies have demonstrated the effects of PAR on motility of the gastrointestinal and biliary tracts, including the esophagus [6,7], stomach [8–10],

duodenum [11], gallbladder [12,13], common bile duct [14] and colon [8,15,16]. In the rat colon, activation of PAR₁, PAR₂ and PAR₄ stimulates contraction [15,16]. In contrast, PAR₁ and PAR₂ activation induces relaxation of the guinea pig colon [8]. In vivo stimulation of both PAR₁ and PAR₂ increases gastrointestinal transit in mice [17]. However, the PAR effects in the internal anal sphincter (IAS) are not known. We hypothesized that activation of PARs may alter IAS motility. The aim of the present study was to investigate the effects mediated by PARs in the guinea pig IAS in vitro. We found that activation of PAR₁ and PAR₂ but not PAR₄ promotes relaxation of the IAS.

2. Materials and methods

Thrombin (from bovine plasma), trypsin (from porcine pancreas, type IX-S), amastatin, N(omega)-Nitro-L-arginine (L-NNA), FSLLR-NH₂ (Phe-Ser-Leu-Leu-Arg-NH₂, inactive PAR₁ control peptide) and all buffer reagents were obtained from Sigma Chemical, St. Louis, MO, USA. TFLLR-NH₂ (Thr-Phe-Leu-Leu-Arg-NH₂, selective PAR₁ agonist), SFLLRN-NH₂ (Ser-Phe-Leu-Leu-Arg-Asn-NH₂, PAR₁ agonist), SLIGRL-NH₂ (Ser-Leu-Ile-Gly-Arg-Leu-NH₂, selective PAR₂ agonist), 2-furoyl-LIGRLO-NH₂ (2-furoyl-Leu-Ile-Gly-Arg-Leu-Orn-NH₂, selective PAR₂ agonist), GYPGQV-NH₂ (Gly-Tyr-Pro-Gly-Gln-Val-NH₂, selective PAR₄

* E-Da Hospital, 1 Yi-Da Road, Yan-Chau, Kaohsiung 824, Taiwan. Tel.: +886 7 6150011x2981; fax: +886 7 6150940.

E-mail addresses: shihchehuang@hotmail.com, huangshihche@gmail.com.

agonist), and AYPGKF-NH₂ (Ala-Tyr-Pro-Gly-Lys-Phe-NH₂, selective PAR₄ agonist) were obtained from American Peptide Company, Sunnyvale, CA, USA. SLIGKV-NH₂ (Ser-Leu-Ile-Gly-Lys-Val-NH₂, selective PAR₂ agonist), GYPGKF-NH₂ (Gly-Tyr-Pro-Gly-Lys-Phe-NH₂, selective PAR₄ agonist) and VKGILS-NH₂ (Val-Lys-Gly-Ile-Leu-Ser-NH₂, inactive PAR₂ control peptide) were purchased from Bachem, Bubendorf, Switzerland. Tetrodotoxin was obtained from Tocris, Cookson, Avonmouth Bristol, UK. Vorapaxar (SCH 530348) and GB 83 were purchased from Axon Medchem BV, Groningen, The Netherlands. RT-PCR reagents and primers for PAR₁ and PAR₂ were purchased from Invitrogen, Carlsbad, CA, and Integrated DNA Technologies, Inc., Coralville, IA, USA, respectively.

2.1. Measurement of relaxation of muscle strips isolated from guinea pig IAS

Male Hartley guinea pigs were obtained from the National Laboratory Animal Center, Taipei, Taiwan. Measurement of relaxation of muscle strips from the IAS was performed according to the procedure published previously [18,19] with modifications [20,21]. Male guinea pigs (350–450 g) were euthanized with CO₂. The anal canal was isolated, cut and placed in standard incubation solution, containing 118 mM NaCl, 25 mM NaHCO₃, 4.7 mM KCl, 14 mM glucose, 1.2 mM NaH₂PO₄, and 1.8 mM CaCl₂, gassed with 95% O₂–5% CO₂. The final pH at 37 °C was 7.40 ± 0.05. The mucosa was removed. The isolated IAS muscle strip, 2 × 10 mm, was tied at both ends with silk sutures and placed in a 5-ml muscle bath containing the standard incubation solution (37 °C) continuously gassed with 95% O₂–5% CO₂. The strip was connected to isometric transducers (FT.03; Grass Technologies, West Warwick, RI, USA), which was connected to an integrated amplifier and computer recording system (BIOPAC Systems, Santa Barbara, CA, USA). The basal tension of the muscle strips was adjusted to 1.0 g. The experiment was started after a 45-min equilibration period. Only the IAS muscle strips that developed spontaneous tone were used. The spontaneous tone developed after the 45-min equilibration was 2.0 ± 0.1 g (*n* = 20).

PAR agonists were added to the muscle bath in a non-cumulative fashion, i.e. with single dose administration [6,7,20]. The relaxation responses were represented as a percentage (% papaverine) of the relaxation to 100 μM papaverine. Only one single dose response, with or without a receptor antagonist, tetrodotoxin or the NO synthase inhibitor, L-NNA, was studied with each preparation. For studies using receptor antagonists, tetrodotoxin and L-NNA, the muscle strips were exposed to the indicated concentrations of receptor antagonists, 1 μM tetrodotoxin and 1 mM L-NNA for 6 min, 15 min and 30 min, respectively, and then to PAR agonists. The muscle strips were exposed to 10 μM amastatin, a peptidase inhibitor, for 15 min, and then to the PAR peptide agonists to reduce peptide degradation [6,7,10]. In preliminary experiments, tetrodotoxin, L-NNA and amastatin did not affect basal tension of the IAS. All procedures were approved by the Institutional Animal Care and Use Committee of E-Da Hospital.

2.2. RT-PCR for detection of mRNA for PAR₁ and PAR₂ in guinea pig IAS

RT-PCR was performed for detection of mRNA for PAR₁, PAR₂ and β-actin in the guinea pig IAS as described previously [22,23] with modifications [14]. Total RNA was isolated from the guinea pig IAS using TRIzol reagent and treated with RNase-free DNase I. The Superscript II RNase H⁻ reverse transcriptase system was employed for the reverse transcription reaction. PCR amplification for PAR₁ was performed with Taq polymerase for 1 cycle at 94 °C for 2 min, followed by 35 cycles at 94 °C for 30 s, 60 °C for 1 min, 72 °C for 1 min, and finally 72 °C for 5 min. Similarly, PCR amplification for PAR₂ was performed with Taq polymerase for 1 cycle at 94 °C for 15 min, followed by 35 cycles at 94 °C for 30 s, 62 °C for 1 min, 72 °C for 1 min, and finally 72 °C for 10 min. PCR amplification for β-actin was performed with Taq polymerase for 1 cycle at 94 °C for 5 min, followed by 35 cycles at 94 °C for 30 s, 62 °C for 1 min, 72 °C for 1 min, and finally 72 °C for 5 min. After amplification,

the PCR products were subjected to electrophoresis on a 1.5% agarose gel containing ethidium bromide and analyzed under UV light against DNA molecular markers. The PAR₁ and PAR₂ PCR products obtained were ligated into the pTZ57R/T vectors (Thermo Scientific, U.S.A.). The ligation mixture was used to transform *E. coli* strain Top10 to produce permanent clones for automated sequencing at Genomics BioSci & Tech (New Taipei City, Taiwan). The following primers were used:

PAR₁: 5'-TGTACGCTCGGTCATGCTC-3' and 5'-GACACAGACGCAGAGGAGGT-3'

PAR₂ [22,23]: 5'-CATGTTCTAGCTACTTCTCTCCTT-3' and 5'-GGTTTTAACACTGGTGGAGCTTGA-3'

β-actin: 5'-CAAGGAGAAGCTATGCTATG-3' and 5'-CAAGAAAGGGTTAACGCAG-3'

The PAR₁ and β-actin primers were designed by Primer3 program and checked by NCBI BLAST for specificity.

2.3. Statistics

Results are expressed as means ± standard error of the mean (SEM). Dose–contraction curves were analyzed with the use of a nonlinear curve fitting program, GraphPad Prism, version 6, (La Jolla, CA, USA), to determine the half-maximal contraction (EC₅₀) values. Statistical evaluation was performed using one-way analysis of variance (ANOVA) with the Dunnett post hoc procedure or Student's *t*-test when appropriate. *P* < 0.05 was considered statistically significant.

3. Results

3.1. Effects of thrombin and PAR₁ peptide agonists in IAS

In the guinea pig IAS strips, thrombin produced detectable relaxation at 1 μM. The highest concentration of thrombin tested (10 μM) caused a relaxant response of 41 ± 6% (*n* = 4) of 100 μM papaverine-induced relaxation (Figs. 1, 2). The PAR₁ peptide agonists TFLLR-NH₂ and SFLLRN-NH₂ caused marked whereas thrombin generated moderate, concentration-dependent relaxation (Figs. 1, 2). TFLLR-NH₂ caused detectable relaxation of IAS muscle strips at 1 μM. The highest concentration (30 μM) of TFLLR-NH₂ tested produced a relaxant response of 81 ± 4% (*n* = 4) of papaverine-induced relaxation (Figs. 1, 2). Similarly, SFLLRN-NH₂ caused detectable relaxation of the IAS muscle strips at 1 μM. The highest concentration (30 μM) of SFLLRN-NH₂ tested produced a relaxation of 81 ± 3% (*n* = 3) of papaverine-induced relaxation. In contrast, the PAR₁ inactive control peptide FSLLR-NH₂, at 30 μM, did not cause contraction or relaxation (Fig. 2). The TFLLR-NH₂-induced relaxation was not altered by 1 μM tetrodotoxin. Specifically, in the presence of 1 μM tetrodotoxin, 10 μM TFLLR-NH₂ produced 62 ± 9% (*n* = 5) papaverine-induced relaxation (*p* > 0.05, compared with TFLLR-NH₂ alone, which generated 74 ± 7%, *n* = 9, of papaverine-induced relaxation).

The relaxant response produced by TFLLR-NH₂ was attenuated by the NO synthase inhibitor L-NNA. In the presence of L-NNA 1 mM, 10 μM TFLLR-NH₂ produced a relaxant response of 38 ± 5% (*n* = 4) of papaverine-induced relaxation (*p* = 0.007 < 0.05, compared with TFLLR-NH₂ alone).

3.2. Effects of trypsin and PAR₂ peptide agonists in IAS

In the guinea pig IAS strips, trypsin caused marked, whereas the PAR₂ peptide agonists 2-furoyl-LIGRLO-NH₂, SLIGKV-NH₂ and SLIGRL-NH₂ produced mild to moderate relaxation of the guinea pig IAS in a concentration-dependent manner (Figs. 1, 3). Trypsin caused detectable relaxation at 300 nM, half-maximal relaxation at 520 ± 50 nM and maximal relaxation at 100 μM, which evoked a relaxant response of 83 ± 1% (*n* = 4) of 100 μM papaverine-induced relaxation (Fig. 3). 2-Furoyl-




Fig. 1. Typical tracings showing relaxations of the guinea pig internal anal sphincter induced by thrombin and PAR₁ selective agonist TFLLR-NH₂ (Thr-Phe-Leu-Leu-Arg-NH₂), trypsin and PAR₂ selective agonist 2-furoyl-LIGRLO-NH₂ (2-furoyl-Leu-Ile-Gly-Arg-Leu-Om-NH₂) but not PAR₄ selective agonist AYPGKF-NH₂ (Ala-Tyr-Pro-Gly-Lys-Phe-NH₂).

LIGRLO-NH₂ was much less potent than trypsin and generated detectable relaxation at 30 μM. The highest concentration (300 μM) of 2-furoyl-LIGRLO-NH₂ tested produced a relaxant response of 58 ± 9% (*n* = 4) of papaverine-induced relaxation (Fig. 3). SLIGRL-NH₂ caused detectable relaxation at 10 μM. The highest concentration (300 μM) of SLIGRL-NH₂ tested generated a relaxant response of 23 ± 8% (*n* = 3) of papaverine-induced relaxation (Fig. 3). Similarly, SLIGKV-NH₂ caused




Fig. 2. Ability of thrombin and PAR₁ peptide agonists TFLLR-NH₂ (Thr-Phe-Leu-Leu-Arg-NH₂) and SFLLRN-NH₂ (Ser-Phe-Leu-Leu-Arg-Asn-NH₂) to cause relaxation of the guinea pig internal anal sphincter. The PAR₁ inactive control peptide FSLLR-NH₂ (Phe-Ser-Leu-Leu-Arg-NH₂) did not cause relaxation. Values are expressed as percent of 100 μM papaverine-induced relaxation. Results given are from at least three experiments. Vertical bars represent ± standard error of the mean (SEM).




Fig. 3. Ability of trypsin and PAR₂ selective agonists 2-furoyl-LIGRLO-NH₂ (2-furoyl-Leu-Ile-Gly-Arg-Leu-Om-NH₂), SLIGKV-NH₂ (Ser-Leu-Ile-Gly-Lys-Val-NH₂) and SLIGRL-NH₂ (Ser-Leu-Ile-Gly-Arg-Leu-NH₂) to cause relaxation of the guinea pig internal anal sphincter. The inactive PAR₂ control peptide VKGILS-NH₂ (Val-Lys-Gly-Ile-Leu-Ser-NH₂) did not cause relaxation. Values are expressed as percent of 100 μM papaverine-induced relaxation. Results given are from at least three experiments. Vertical bars represent ± standard error of the mean (SEM).

detectable relaxation at 30 μM. The highest concentration (300 μM) of SLIGKV-NH₂ tested produced a relaxant response of 25 ± 6% (*n* = 3) of papaverine-induced relaxation (Fig. 3). In contrast, the PAR₂ inactive control peptide VKGILS-NH₂ did not cause contraction or relaxation when tested at concentrations up to 300 μM (Fig. 3). The trypsin-evoked relaxation was not altered by tetrodotoxin. Specifically, in the presence of 1 μM tetrodotoxin, trypsin (10 μM) produced a relaxant response of 72 ± 5% (*n* = 5) of papaverine-induced relaxation (*p* > 0.05, compared with trypsin alone, which evoked a relaxant response 76 ± 5% (*n* = 6) of papaverine-induced relaxation).

The relaxant response produced by trypsin was attenuated by L-NNA. In the presence of 1 mM L-NNA, 1 μM trypsin produced a relaxant response of 30 ± 3% (*n* = 4) of papaverine-induced relaxation (*p* < 0.001, compared with trypsin alone, 63 ± 5%, *n* = 4).

3.3. No effects of PAR₄ agonists on IAS contraction or relaxation

The PAR₄ peptide agonists AYPGKF-NH₂ (Fig. 1), GYPGKF-NH₂ and GYPGQV-NH₂ (data not shown), at concentrations up to 500 μM, did not cause contraction or relaxation of the guinea pig IAS strips.

3.4. Effects of PAR₁ and PAR₂ antagonists on thrombin or trypsin-induced IAS relaxation

The selective PAR₁ antagonist vorapaxar (3 μM) and PAR₂ antagonist GB 83 (3 μM) alone did not cause contraction or relaxation (data not shown). In the IAS, vorapaxar abolished whereas GB 83 did not alter the thrombin response (Fig. 4). Specifically, the relaxation caused by 3 μM thrombin alone was 44 ± 8% (*n* = 4) of papaverine-induced relaxation, whereas the relaxations caused by thrombin with 3 μM vorapaxar and 3 μM GB 83 were 0 ± 0% (*n* = 5) and 47 ± 6% (*n* = 5), respectively (*p* < 0.001 and *p* = 0.79, respectively, compared with thrombin alone using ANOVA; Fig. 4). Furthermore, GB 83 markedly inhibited whereas vorapaxar did not alter the trypsin response significantly. Specifically, the relaxation caused by 1 μM trypsin alone was 63 ± 5% (*n* = 5) of papaverine-induced relaxation, whereas the relaxations caused by trypsin with 3 μM GB 83 and 3 μM vorapaxar were 15 ± 9% (*n* = 4) and 46 ± 6% (*n* = 4), respectively (*p* < 0.001 and *p* = 0.09, respectively, compared with trypsin alone using ANOVA; Fig. 4).

3.5. PAR₁ and PAR₂ expression in IAS

RT-PCR was performed to examine the mRNA expression of PAR₁, PAR₂, and β-actin in the guinea pig IAS. As shown in Fig. 5, amplification of the cDNA yielded 521, 472, and 532 base-pair products for PAR₁, PAR₂, and β-actin, respectively, as predicted [22,23]. Sequencing of the




Fig. 4. Ability of PAR₁ antagonist vorapaxar and PAR₂ antagonist GB 83 to inhibit thrombin (upper panel) or trypsin (lower panel)-induced relaxation of the guinea pig internal anal sphincter. Values are expressed as percent of 100 μ M papaverine-induced relaxation. Results given are from at least four experiments. Vertical bars represent \pm standard error of the mean (SEM).

PAR₁ and PAR₂ RT-PCR products and blasting against the NCBI nucleotide database confirmed that they represented partial sequences of guinea pig PAR₁ and PAR₂ (Supplement Fig. 1).

4. Discussion

PAR activation modulates gastrointestinal motility from the esophagus to colon. The present study demonstrates that PAR₁ and PAR₂ activation can also relax the IAS. In addition, this study unveils that NO is involved in both PAR₁ and PAR₂-mediated relaxation of the guinea pig IAS, similar to the guinea pig lower esophageal sphincter [7].

In the isolated IAS strips, thrombin and the PAR₁ peptide agonists TFLLR-NH₂ and SFLLRN-NH₂ as well as trypsin and the PAR₂ peptide agonists 2-furoyl-LIGRLO-NH₂, SLIGRL-NH₂ and SLIGKV-NH₂ evoked concentration-dependent relaxation. Furthermore, the PAR₁ antagonist vorapaxar and PAR₂ antagonist GB 83 specifically inhibited the thrombin and trypsin responses, respectively. In addition, RT-PCR identified




Fig. 5. Reverse transcription polymerase chain reaction (RT-PCR) analyses of the expression of PAR₁, PAR₂, and β -actin mRNA in the guinea pig internal anal sphincter. Total RNA was extracted from the internal anal sphincter, reverse transcribed, and amplified using PAR₁, PAR₂ or β -actin-specific primers. The amplified products were electrophoresed on an agarose gel. Results presented are representative of three experiments. Lane 1, PAR₁; Lane 2, PAR₂; Lane 3, β -actin.

the expression of PAR₁ and PAR₂ in the guinea pig IAS. This indicates that both PAR₁ and PAR₂ mediate relaxation in the guinea pig IAS.

The PAR₁ and PAR₂-mediated IAS relaxation might involve NO as the TFLLR-NH₂ and trypsin-induced relaxant responses were attenuated by the NO synthase inhibitor L-NNA. This is in agreement with previous studies showing that NO is one of the major signaling pathways for relaxation in the IAS [24]. All three PAR₄ peptide agonists, AYPGKF-NH₂, GYPGKF-NH₂ and GYPGQV-NH₂, exhibited no contraction or relaxation in IAS strips, suggesting that PAR₄ activation does not affect IAS motility. Previously, PAR₄ agonists also were found to have no motility effects in the esophagus, duodenum and gallbladder [6,7,11–13]. However, PAR₄ agonists were reported to elicit contraction of the colon and relaxation of the common bile duct [14,16].

In the gastrointestinal tract, PAR₁ and PAR₂ stimulate contraction of the human esophagus [6], guinea pig and rat stomach [9,10], human and guinea pig gallbladder [12,13] as well as rat colon [15]. In addition, PAR₁ and PAR₂ activation evokes relaxation of the guinea pig lower esophageal sphincter [7] and guinea pig colon [8]. Both PAR₁ and PAR₂ elicit a dual action, i.e., relaxation followed by contraction, in the mouse gastric fundus [8] and rat duodenum [11]. Furthermore, the results in the present study showed that both PAR₁ and PAR₂ mediate relaxation of the guinea pig IAS. Thus, PAR₁ and PAR₂ mediate similar motility effects and are the predominant PAR subtypes regulating gastrointestinal motility, while PAR₄ has minor impact in this aspect. The IAS basal tone is myogenic but altered by external neurohumoral signals [24]. Previous studies have shown that IAS relaxations are mediated by β -adrenoceptors, muscarinic, purinergic, endothelin and angiotensin AT₂ receptors [19, 25–28]. In contrast, stimulations of α -adrenoceptors and angiotensin AT₁ receptors result in contractions [25,26,29]. The present study showed that PAR₁ and PAR₂ mediate relaxation in the guinea pig IAS under physiological conditions *ex vivo*. PAR₁ and PAR₂ might regulate the basal tone of IAS, which plays an important role in maintaining the anal continence. Previous studies strongly suggested that PAR₁ and PAR₂ are involved in the pathogenesis of colitis [2]. Whether PAR₁ and PAR₂ are involved in the pathogenesis of anorectal motility disorders is not known. Potent PAR agonists and antagonists are being developed recently [2]. Further studies using these agonists and antagonists are warranted to investigate the involvement of PARs in anorectal motility disorders. Currently, glyceryl trinitrate and the calcium channel blocker nifedipene are commonly used for topical treatment of chronic anal fissure. However, there is a moderate incidence of side effects and the response is inadequate in some patients [30]. Our findings may help the development of new therapeutic agents to target the IAS. PAR₁ and PAR₂ agonists, which can relax IAS, are of potential therapeutic importance in chronic anal fissure or anal pain after hemorrhoidectomy [25,30–32]. Studies on PAR effects in the human IAS are needed to investigate these potential applications [33].

In conclusion, these results provide evidence that both PAR₁ and PAR₂ mediate guinea pig IAS relaxation through the NO pathway. PAR₁ and PAR₂ may regulate IAS tone and might be potential therapeutic targets for anal motility disorders including anal fissure.

Conflict of interest

The author declares that there are no conflicts of interest.

Acknowledgments

This work was presented, in part, at the Digestive Disease Week 2011, 7–10 May, 2011, Chicago, Illinois, USA, and was supported by the National Science Council (102-2314-B-214-003-MY3), E-Da Hospital (EDAHT101021) and Buddhist Tzu Chi General Hospital. The author thanks Dr. Chung Fang Lai for helpful discussion, and Ling-Jung Chiu, Chien-Pin Wang, Yu-Shyuan Wang, Cai-Jing Lee and Chiung-Fang Hsu for excellent technical assistance.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.regpep.2014.03.001>.

References

- [1] Vergnolle N. Protease-activated receptors as drug targets in inflammation and pain. *Pharmacol Ther* 2009;123:292–309.
- [2] Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD. Targeting proteinase activated receptors: therapeutic potential and challenges. *Nat Rev Drug Discov* 2012;11:69–86.
- [3] Cattaruzza F, Lyo V, Jones E, Pham D, Hawkins J, Kirkwood K, et al. Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. *Gastroenterology* 2011;141:1864–74 [e1–3].
- [4] Kawabata A, Matsunami M, Sekiguchi F. Gastrointestinal roles for proteinase-activated receptors in health and disease. *Br J Pharmacol* 2008;153(Suppl. 1): S230–40.
- [5] Tognetto M, Trevisani M, Maggiore B, Navarra G, Turini A, Guerrini R, et al. Evidence that PAR-1 and PAR-2 mediate prostanoid-dependent contraction in isolated guinea-pig gallbladder. *Br J Pharmacol* 2000;131:689–94.
- [6] Chang BS, Chang JC, Huang SC. Proteinase-activated receptors 1 and 2 mediate contraction of human oesophageal muscularis mucosae. *Neurogastroenterol Motil* 2010;22:93–7.
- [7] Huang SC. Protease-activated receptor-1 (PAR1) and PAR2 but not PAR4 mediate relaxations in lower esophageal sphincter. *Regul Pept* 2007;142:37–43.
- [8] Cocks TM, Sozzi V, Moffatt JD, Selemidis S. Protease-activated receptors mediate apamin-sensitive relaxation of mouse and guinea pig gastrointestinal smooth muscle. *Gastroenterology* 1999;116:586–92.
- [9] Hollenberg MD, Saifeddine M, Al-Ani B, Gui Y. Proteinase-activated receptor 4 (PAR4): action of PAR4-activating peptides in vascular and gastric tissue and lack of cross-reactivity with PAR1 and PAR2. *Can J Physiol Pharmacol* 1999;77:458–64.
- [10] Saifeddine M, Al-Ani B, Sandhu S, Wijesuriya SJ, Hollenberg MD. Contractile actions of proteinase-activated receptor-derived polypeptides in guinea-pig gastric and lung parenchymal strips: evidence for distinct receptor systems. *Br J Pharmacol* 2001;132:556–66.
- [11] Kawabata A, Kuroda R, Nishikawa H, Kawai K. Modulation by protease-activated receptors of the rat duodenal motility in vitro: possible mechanisms underlying the evoked contraction and relaxation. *Br J Pharmacol* 1999;128:865–72.
- [12] Lee MC, Huang SC. Proteinase-activated receptor-1 (PAR1) and PAR2 but not PAR4 mediate contraction in human and guinea-pig gallbladders. *Neurogastroenterol Motil* 2008;20:385–91.
- [13] Schmidt VA, Nierman WC, Maglott DR, Cupit LD, Moskowitz KA, Wainer JA, et al. The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a Par gene cluster and characterization in vascular endothelial cells and platelets. *J Biol Chem* 1998;273:15061–8.
- [14] Huang SC. Effects of trypsin, thrombin and proteinase-activated receptors on guinea pig common bile duct motility. *Regul Pept* 2012;179:1–5.
- [15] Mulè F, Baffi MC, Capparelli A, Pizzuti R. Involvement of nitric oxide and tachykinins in the effects induced by protease-activated receptors in rat colon longitudinal muscle. *Br J Pharmacol* 2003;139:598–604.
- [16] Mulè F, Pizzuti R, Capparelli A, Vergnolle N. Evidence for the presence of functional protease activated receptor 4 (PAR4) in the rat colon. *Gut* 2004;53:229–34.
- [17] Kawabata A, Kuroda R, Nagata N, Kawao N, Masuko T, Nishikawa H, et al. In vivo evidence that protease-activated receptors 1 and 2 modulate gastrointestinal transit in the mouse. *Br J Pharmacol* 2001;133:1213–8.
- [18] Chakder S, Rattan S. Mechanisms and sites of action of endothelins 1 and 2 on the opossum internal anal sphincter smooth muscle tone in vitro. *J Pharmacol Exp Ther* 1999;288:239–46.
- [19] Lim SP, Muir TC. Mechanisms underlying the electrical and mechanical responses of the guinea-pig internal anal sphincter to field stimulation and to drugs. *Br J Pharmacol* 1985;86:427–37.
- [20] Huang SC. Endothelin A receptors mediate relaxation of guinea pig internal anal sphincter through cGMP pathway. *Neurogastroenterol Motil* 2010;22:1009–e264.
- [21] von Schrenck T, Heinz-Erian P, Moran T, Mantey SA, Gardner JD, Jensen RT. Neurokinin B receptor in esophagus: evidence for subtypes of bombesin receptors. *Am J Physiol* 1989;256:G747–58.
- [22] Corvera CU, Déry O, McConalogue K, Gamp P, Thoma M, Al-Ani B, et al. Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through proteinase-activated receptors-1 and -2. *J Physiol* 1999;517:741–56.
- [23] Reed DE, Barajas-Lopez C, Cottrell G, Velazquez-Rocha S, Dery O, Grady EF, et al. Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of guinea-pig submucosal neurons. *J Physiol* 2003;547:531–42.
- [24] Rattan S, Singh J. Basal internal anal sphincter tone, inhibitory neurotransmission, and other factors contributing to the maintenance of high pressures in the anal canal. *Neurogastroenterol Motil* 2011;23:3–7.
- [25] Cook TA, Brading AF, Mortensen NJ. The pharmacology of the internal anal sphincter and new treatments of ano-rectal disorders. *Aliment Pharmacol Ther* 2001;15:887–98.
- [26] de Godoy MA, Rattan S. Translocation of AT1- and AT2-receptors by higher concentrations of angiotensin II in the smooth muscle cells of rat internal anal sphincter. *J Pharmacol Exp Ther* 2006;319:1088–95.
- [27] McDonnell B, Hamilton R, Fong M, Ward SM, Keef KD. Functional evidence for purinergic inhibitory neuromuscular transmission in the mouse internal anal sphincter. *Am J Physiol Gastrointest Liver Physiol* 2008;294:G1041–51.
- [28] Rathi S, Kazerounian S, Banwait K, Schulz S, Waldman SA, Rattan S. Functional and molecular characterization of beta-adrenoceptors in the internal anal sphincter. *J Pharmacol Exp Ther* 2003;305:615–24.
- [29] Mills K, Hausman N, Chess-Williams R. Characterization of the alpha1-adrenoceptor subtype mediating contractions of the pig internal anal sphincter. *Br J Pharmacol* 2008;155:110–7.
- [30] Khaikin M, BashankaeV B, Sands D, Weiss EG, Zbar A, Wexner SD. The effect of topical anal captopril on resting anal pressure in healthy volunteers: the first human pilot study. *Tech Coloproctol* 2014;18:39–43.
- [31] Dhawan S, Chopra S. Nonsurgical approaches for the treatment of anal fissures. *Am J Gastroenterol* 2007;102:1312–21.
- [32] Perrotti P, Dominici P, Grossi E, Cerutti R, Antropoli C. Topical nifedipine with lidocaine ointment versus active control for pain after hemorrhoidectomy: results of a multicentre, prospective, randomized, double-blind study. *Can J Surg* 2010;53:17–24.
- [33] Ballester C, Sarriá B, García-Granero E, Mata M, Milara J, Morcillo EJ, et al. Relaxation by beta 3-adrenoceptor agonists of the isolated human internal anal sphincter. *Life Sci* 2010;86:358–64.